Tag Archive > capecitabine

“Complete Remission” in Hormone Refractory Prostate Cancer

» 01 June 2007 » In Clinical trials, Hormone refractory, Prostate Cancer » Comments Off

From ASCO annual general meeting, 2007, comes this abstract of a study by A. Reichle, B. Walter, A. Berand, M. Vogelhuber, K. Bross, J. Wilke, W. Wieland, R. Andreesen, S. Rogenhofer.

Background: The present multi-centre phase II study was designed to support the hypothesis that networking agents binding to ubiquitous accessible targets in metastatic hormone-refractory prostate cancer (HRPC) may counteract neoplasia-specific aberrant cellular functions, thereby mediating objective response (primary endpoint).

Continue reading...

Tags: ,